Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Sustained viral response 12 weeks	16047	16189	Overall, by ITT analysis, SVR12 was achieved in 92% (46/50, 95% CI 81‐97) of patients treated with GLE + PIB with or without RBV for 12 weeks.
Glecaprevir 200mg + pibrentasvir 80 mg 	Glecaprevir 300mg + pibrentasvir 120 mg	Discontinuation due to adverse events	-1	-1	<td align="left" colspan="1" rowspan="1" style="padding-left:10%" valign="top">Serious</td><td align="center" colspan="1" rowspan="1" valign="top">1 (16.7)<xref ref-type="fn" rid="hep29081-note-0010">a</xref><NEWLINE> <NEWLINE></td><td align="center" colspan="1" rowspan="1" valign="top">1 (4.5)<xref ref-type="fn" rid="hep29081-note-0011">b</xref><NEWLINE> <NEWLINE></td><td align="center" colspan="1" rowspan="1" valign="top">0</td>
Glecaprevir 200mg + pibrentasvir 80 mg 	Glecaprevir 300mg + pibrentasvir 120 mg	Discontinuation due to adverse events	20475	20508	Discontinuation as a result 0 0 0
Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Discontinuation due to adverse events	19897	19965	No patient prematurely discontinued treatment due to adverse events.
Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Discontinuation due to adverse events	20475	20508	Discontinuation as a result 0 0 0
Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Virologic failure rate	16589	16704	The rates of virologic failure were identical (1/22, 5%) with or without administration of RBV (arm B versus arm C)
Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Virologic failure rate	17019	17202	Two confirmed virologic failures were observed; both patients were compliant and had on‐treatment drug levels of GLE and PIB that were consistent with those observed in other patients
Glecaprevir 300mg + pibrentasvir 120 mg + ribavirin 	Glecaprevir 300mg + pibrentasvir 120 mg	Virologic failure rate	22302	22467	The addition of RBV to the GLE + PIB regimen had no apparent impact on response as the rates of virologic failure were identical in arms B and arm C by mITT analysis
